Shares of Kane Biotech Inc. (CVE:KNE – Get Free Report) fell 20% on Tuesday . The stock traded as low as C$0.02 and last traded at C$0.02. 132,200 shares were traded during trading, a decline of 23% from the average daily volume of 171,277 shares. The stock had previously closed at C$0.03.
Kane Biotech Stock Down 20.0%
The company has a current ratio of 0.61, a quick ratio of 0.39 and a debt-to-equity ratio of -197.52. The stock has a 50 day simple moving average of C$0.03 and a 200 day simple moving average of C$0.03. The firm has a market capitalization of C$4.10 million, a PE ratio of -1.00 and a beta of 1.08.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Featured Stories
- Five stocks we like better than Kane Biotech
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
